Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD

Published on October 7, 2021

Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.

Continue reading on website
Other news

The Medical Aesthetics and Plastic Surgery Industry Is Booming – And There’s No End in Sight

October 7, 2021
For more than a year now, a global health crisis has forced lockdowns in countries all around the world. And plenty of industries have suffered from it. But there’s one...

DTE Energy (DTE) to Develop 20MW Solar Park in Michigan

October 7, 2021
DTE Energy (DTE) is going to build a 20MW solar facility to support Michigan's City of Ann Arbor and Pittsfield Township, which will be the largest solar project in the...